[{"id":"3e645071-4216-4aec-a0bd-0e6e40f1d02a","acronym":"S1607","url":"https://clinicaltrials.gov/study/NCT02965716","created_at":"2021-01-18T14:34:36.597Z","updated_at":"2024-07-02T16:35:26.748Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT02965716 - S1607","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86","pipe":" | ","alterations":" CD8 expression","tags":["TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/05/2024","study_completion_date":" 11/05/2024","last_update_posted":"2023-12-08"},{"id":"d7250f67-4645-4aee-9249-1bb54b6cd454","acronym":"TANOs","url":"https://clinicaltrials.gov/study/NCT04867421","created_at":"2021-04-30T11:55:07.437Z","updated_at":"2024-07-02T16:36:09.921Z","phase":"","brief_title":"Neutrophils in Bone Sarcomas","source_id_and_acronym":"NCT04867421 - TANOs","lead_sponsor":"Université de Reims Champagne-Ardenne","biomarkers":" PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-05-25"},{"id":"da30e10f-e520-4977-a09e-302d2f4b6b4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04001101","created_at":"2021-01-18T19:39:57.498Z","updated_at":"2024-07-02T16:36:20.116Z","phase":"Phase 2","brief_title":"Anti-PD-1 +/- RT for MSI-H Solid Tumors","source_id_and_acronym":"NCT04001101","lead_sponsor":"University of Colorado, Denver","biomarkers":" MSI • CD8 • LAG3 • IL2RA • ICOS • CD1C • CD80","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD8 • LAG3 • IL2RA • ICOS • CD1C • CD80"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2019","start_date":" 10/10/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/17/2021","study_completion_date":" 11/17/2021","last_update_posted":"2021-11-30"},{"id":"46c08f17-26c5-4730-b84c-c4364ca8da5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02545361","created_at":"2021-01-19T08:29:28.970Z","updated_at":"2024-07-02T16:37:07.837Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients","source_id_and_acronym":"NCT02545361","lead_sponsor":"Kahr Medical","biomarkers":" FAS • CD80 • CD86","pipe":"","alterations":" ","tags":["FAS • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KAHR-102 • dexamethasone injection"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2018-08-16"},{"id":"1d01f9a8-868a-4cb0-a3c0-ae82cf999658","acronym":"","url":"https://clinicaltrials.gov/study/NCT00726739","created_at":"2022-10-13T14:56:06.542Z","updated_at":"2024-07-02T16:37:15.208Z","phase":"Phase 2","brief_title":"Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma","source_id_and_acronym":"NCT00726739","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD80","pipe":"","alterations":" ","tags":["CD80"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 06/01/2011","primary_completion_date":" 06/01/2011","study_txt":" Completion: 06/01/2011","study_completion_date":" 06/01/2011","last_update_posted":"2017-12-28"},{"id":"131825b5-f2d5-4147-9680-3719eface49a","acronym":"GeparOcto","url":"https://clinicaltrials.gov/study/NCT02125344","created_at":"2021-01-18T09:50:50.151Z","updated_at":"2025-02-25T14:00:27.083Z","phase":"Phase 3","brief_title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","source_id_and_acronym":"NCT02125344 - GeparOcto","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • ER • PIK3CA • PGR • CD80","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PIK3CA mutation • ER negative","tags":["HER-2 • ER • PIK3CA • PGR • CD80"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PIK3CA mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • Myocet (non-pegylated liposomal doxorubicin) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 961","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 01/30/2017","study_completion_date":" 01/30/2017","last_update_posted":"2017-07-13"}]